-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemogenovatucel-T in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemogenovatucel-T in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemogenovatucel-T in Uterine Cancer Drug Details: Gemogenovatucel-T (Vigil) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemogenovatucel-T in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemogenovatucel-T in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemogenovatucel-T in Cervical Cancer Drug Details: Gemogenovatucel-T (Vigil) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izuralimab in Leiomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Izuralimab in Leiomyosarcoma Drug Details: XmAb-23104 is under development for the treatment of melanoma, cervical...
-
Sector Analysis
Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional ovarian cancer therapies was $3.2B in 2021. The increasing number of ovarian cancer cases will drive market growth during the forecast period. Ovarian Cancer–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Ovarian Cancer–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The ovarian cancer–cell and gene therapies...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma Drug Details RNAi gene therapy...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...